SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma
Authors:
- 30 December 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 22 (2) , 223-231
Abstract
Signal sequence receptor subunit delta (SSR4) gene is reported to encode the translocon-associated protein δ and related with the human immune regulation. However, the expression of SSR4 in colon a...Keywords
Funding Information
- Nanjing First Hospital (No. 1521)
This publication has 37 references indexed in Scilit:
- Duration of Adjuvant Chemotherapy for Stage III Colon CancerNew England Journal of Medicine, 2018
- TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune CellsCancer Research, 2017
- Lymphotoxin signalling in tertiary lymphoid structures and immunotherapyCellular & Molecular Immunology, 2017
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Research, 2017
- Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancerOncoImmunology, 2017
- Heterogeneity of colon cancer: from bench to bedsideESMO Open, 2017
- Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer modelNature Materials, 2016
- Expanding the Molecular and Clinical Phenotype of SSR4-CDGHuman Mutation, 2015
- A new congenital disorder of glycosylation caused by a mutation in SSR4, the signal sequence receptor 4 protein of the TRAP complexHuman Molecular Genetics, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012